



ASX Announcement

Medlab is pleased to announce the completion of the Australian Nutraceuticals (VMS) business divestment to PharmaCare

SYDNEY, November 11, 2021 - Medlab Clinical LTD (ASX: MDC) is pleased to announce transaction completion of the Australian only rights for the Medlab branded nutraceutical (VMS) lines.

Key Summary:

- The transaction has cash contributions of \$2.2M from PharmaCare in consideration of the transfer of specific Medlab IP, pre-paid stock, stock on order and stock on hand.
- Post completion, as well as R&D grant, Medlab is in a strong cash position with \$13M in the bank.
- This deal enables Medlab to make savings of around \$2M annually on operating expenses and better align its focus on areas of strategic growth.
- Monies received and phase one deal complete.
- A further phase two being a two year earnout is in place to be the greater of \$250K or 5% of net Sales per year during the first and second year (an incremental >\$500K minimum over two years).
- We have retained the ownership of our R&D and both Companies have agreed to work together on future product development, hence providing ongoing innovation to PharmaCare as well as an ongoing income stream to Medlab.
- Medlab reserves all its nutraceuticals rights for the rest of the world and are currently actively pursuing opportunities.
- Subsequent to this transaction, Medlab is fully focused on commercialising its global Biotech assets, regulatory approvals, partnering and early market access initiatives. See below for more information about Medlab.

ENDS

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

About Medlab Clinical:

Medlab Clinical Ltd (ASX: MDC) is pioneering the development and commercialisation of a pharmaceutical delivery platform, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability. Medlab's pipeline comprises a number of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. Patented lead drug candidate NanaBis™ has been developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis™ may be equally effective in non-cancer neuropathic pain. NanoCelle®, the patented delivery platform is wholly owned by Medlab and developed in Medlab's owned OGTR (Office of the Gene Technology Regulator) Registered Laboratory. NanoCelle® is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia (Head Office), USA, and the UK. For more information, please visit www.medlab.co

Medlab – better medicines, better patient care

Medlab Clinical
Mr Kerem Kaya, CFO
T: +61 2 7201 0096
Kerem_kaya@medlab.co

Medlab US Investor Relations
Laine Yonker
lyonker@edisongroup.com